Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Recruiting · NCT06970145 · Registry updated 2025-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, craniopharyngioma, neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2025-11-18 | NCT06970145 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanfang Hospital, Southern Medical University | 248 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Southern Medical University, Nanfang Hospital, Department of Neurosurgery | Guangzhou | China | 2 |